0.50 / AMA PRA Category 1 CreditTM 0.50 / CE for Pharmacists (0.05 CEU) 0.10 / IACET CEU
Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from Merck & Company.
The purpose of this activity is to provide clinicians who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance.
I. VAP/HAP: Case Presentation II. Challenges with P. aeruginosa III. Ensuring Effectiveness of Antibiotics and Reducing Resistance IV. New and Emerging Approaches to Gram-negative Organisms V. Antimicrobial Susceptibility Testing VI. Molecular Epidemiology of Antibiotic Resistance VII. cUTIs: Case Presentation and Panel Discussion
This activity is intended for ID specialists, hospitalists, pharmacists and other healthcare professionals who care for patients with serious infections.
Upon proper completion of this activity, participants should be better able to:
Summarize the burden of HAP/VAP and challenges associated with its management
Outline patient and clinical factors that increase risks for resistant Gram-negative pathogens
Describe strategies to optimize antimicrobial therapy to ensure effectiveness and reduce resistance
Conflict of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE/CPE activity.
George H. Karam, MD Paula Garvey Manship Chair of Medicine Head of the LSUHSC Dept. of Internal Medicine Louisiana State University Baton Rouge, LA
Dr. Karam discloses the following: Advisory Board: Merck, Paratek, and Shionogi Consultant: Shionogi and Tetraphase Honoraria Recipient: Merck
James Lewis, II, PharmD, FIDSA Infectious Disease Clinical Pharmacy Supervisor Co-Director of Antibiotic Stewardship Department of Pharmacy Oregon Health & Science University Portland, OR
Dr. Lewis discloses the following: Consultant: Merck and Tetraphase
Jason M. Pogue, PharmD, BCPS‐ID Clinical Pharmacist, Infectious Diseases Sinai‐Grace Hospital Detroit Medical Center Clinical Assistant Professor of Medicine Wayne State University School of Medicine Detroit, MI
Dr. Pogue discloses the following: Consultant: Melinta, Merck, Nabriva, Shionogi, and Tetraphase Speakers Bureau: Melinta and Merck Grant Support: Merck
Patricia (Trish) Simner, PhD, D(ABMM) Director of Medical Bacteriology and Parasitology Laboratories Associate Professor of Pathology Johns Hopkins School of Medicine Baltimore, MD
Dr. Simner discloses the following: Consultant: Accelerate Diagnostics, CosmosID, OpGen Inc., and Roche Diagnostics Research Grants: Accelerate Diagnostics, Affinity Biosensors, Check-Points BV, Hardy Diagnostics, and OpGen Inc.
Accredited Provider Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Pharmacists
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 0.50 contact hours.
ACPE Universal Activity Number: 0396-0000-19-006-H01-P
Activity Type: Knowledge
The Academy for Continued Healthcare Learning (ACHL) has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET). In obtaining this accreditation, the ACHL has demonstrated that it complies with the ANSI/IACET Standard which is recognized internationally as a standard of good practice. As a result of the Authorized Provider status, ACHL is authorized to offer IACET CEUs for programs that qualify under the ANSI/IACET Standard.
ACHL is authorized by IACET to offer 0.10 CEU for this program.
IACET CEUs are accepted by the American Nurses Association. Contact your licensing agency for details.
Disclosure of Unlabeled Use
Novel antibiotics and available antibiotics under investigation for use in different types of serious infections.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available and emailed, please be sure to check spam/junk mailbox. There is no fee to participate in the activity or for the generation of the certificate. Your certificate will be saved on the ACHL website and will not be available in your myCME CME History.
CPE credit will be submitted to CPE Monitor® on the first day of each month.Your certificate will be saved on the ACHL website and will not be available in your myCME CME History.